PMID- 31821937
OWN - NLM
STAT- MEDLINE
DCOM- 20200713
LR  - 20200713
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 78
DP  - 2020 Jan
TI  - Xanthone suppresses allergic contact dermatitis in vitro and in vivo.
PG  - 106061
LID - S1567-5769(19)32174-5 [pii]
LID - 10.1016/j.intimp.2019.106061 [doi]
AB  - Xanthone is a phenolic compound found in a few higher plant families; it has a 
      variety of biological activities, including antioxidant, anti-inflammatory, and 
      anticancer properties. However, the molecular and cellular mechanisms underlying 
      the activity of xanthone in allergic contact dermatitis (ACD) remain to be 
      explored. Therefore, this study aimed to investigate the regulatory effects of 
      xanthone in ACD in human keratinocytes (HaCaT cell), and human mast cell line 
      (HMC-1 cell) in vitro and in an experimental murine model. The results 
      demonstrated that treatment with xanthone reduced the production of 
      pro-inflammatory cytokines and chemokines including interleukin (IL)-1beta, IL-6, 
      IL-8, and expression of chemokines thymus and activation-regulated chemokine 
      (TARC) and macrophage-derived chemokine (MDC) in tumor necrosis factor (TNF)-alpha 
      and interferon (IFN)-gamma-stimulated HaCaT cells. Xanthone also suppressed the 
      production of pro-inflammatory cytokines, chemokines, and allergic mediators in 
      phorbol myristate acetate/A23187 calcium ionophore (PMACI)-stimulated HMC-1 
      cells. Xanthone significantly suppressed the phosphorylation of mitogen-activated 
      protein kinases (MAPKs) and nuclear factor-kappa B (NF-kappaB) and activation of 
      caspase-1 signaling pathway in vitro model. Additionally, xanthone administration 
      alleviated 2,4-dinitrofluorobenzene (DNFB)-induced atopic dermatitis like-skin 
      lesion by reducing the serum levels of immunoglobulin E (IgE), histamine, and 
      pro-inflammatory cytokines and suppressing MAPKs phosphorylation. Xanthone 
      administration also inhibited mortality due to compound 48/80-induced 
      anaphylactic shock and suppressed the passive cutaneous anaphylaxis (PCA) 
      reaction mediated by IgE. Collectively, these results suggest that xanthone has a 
      potential for use in the treatment of allergic inflammatory diseases.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Aye, Aye
AU  - Aye A
AD  - Department of Lifestyle Medicine, Chonbuk National University, 79 Gobongro, 
      Iksan, Jeollabuk-do 54596, Republic of Korea; Department of Oriental Medicine 
      Resources, Chonbuk National University, 79 Gobong-ro, Iksan, Jeollabuk-do 54596, 
      Republic of Korea. Electronic address: veryproblem.aa@gmail.com.
FAU - Song, Young-Jae
AU  - Song YJ
AD  - Department of Oriental Medicine Resources, Chonbuk National University, 79 
      Gobong-ro, Iksan, Jeollabuk-do 54596, Republic of Korea. Electronic address: 
      dudwoid@naver.com.
FAU - Jeon, Yong-Deok
AU  - Jeon YD
AD  - Department of Oriental Medicine Resources, Chonbuk National University, 79 
      Gobong-ro, Iksan, Jeollabuk-do 54596, Republic of Korea; Korea Zoonosis Research 
      Institute, Chonbuk National University, Iksan, Jeollabuk-do 54531, Republic of 
      Korea. Electronic address: dugicom@nate.com.
FAU - Jin, Jong-Sik
AU  - Jin JS
AD  - Department of Oriental Medicine Resources, Chonbuk National University, 79 
      Gobong-ro, Iksan, Jeollabuk-do 54596, Republic of Korea. Electronic address: 
      jongsik.jin@jbnu.ac.kr.
LA  - eng
PT  - Journal Article
DEP - 20191209
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Xanthones)
RN  - 37H9VM9WZL (Calcimycin)
RN  - 4091-50-3 (p-Methoxy-N-methylphenethylamine)
RN  - 9749WEV0CA (xanthone)
RN  - D241E059U6 (Dinitrofluorobenzene)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
SB  - IM
MH  - Administration, Oral
MH  - Anaphylaxis/chemically induced/*drug therapy/immunology
MH  - Animals
MH  - Anti-Allergic Agents/*pharmacology/therapeutic use
MH  - Calcimycin/administration & dosage/immunology
MH  - Cell Line
MH  - Dermatitis, Allergic Contact/*drug therapy/immunology/pathology
MH  - Dinitrofluorobenzene/administration & dosage/immunology
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical
MH  - Humans
MH  - Inflammation Mediators/metabolism
MH  - Keratinocytes/drug effects/immunology/pathology
MH  - Male
MH  - Mast Cells/drug effects/immunology/pathology
MH  - Mice
MH  - Mitogen-Activated Protein Kinases/immunology/metabolism
MH  - Phosphorylation/drug effects/immunology
MH  - Skin/*drug effects/immunology/pathology
MH  - Tetradecanoylphorbol Acetate/administration & dosage/immunology
MH  - Xanthones/*pharmacology/therapeutic use
MH  - p-Methoxy-N-methylphenethylamine/immunology/toxicity
OTO - NOTNLM
OT  - Allergic contact dermatitis
OT  - Anaphylactic shock
OT  - Keratinocytes
OT  - Mast cells
OT  - Xanthone
EDAT- 2019/12/11 06:00
MHDA- 2020/07/14 06:00
CRDT- 2019/12/11 06:00
PHST- 2019/09/25 00:00 [received]
PHST- 2019/11/14 00:00 [revised]
PHST- 2019/11/14 00:00 [accepted]
PHST- 2019/12/11 06:00 [pubmed]
PHST- 2020/07/14 06:00 [medline]
PHST- 2019/12/11 06:00 [entrez]
AID - S1567-5769(19)32174-5 [pii]
AID - 10.1016/j.intimp.2019.106061 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2020 Jan;78:106061. doi: 10.1016/j.intimp.2019.106061. Epub 
      2019 Dec 9.